| 000 -LEADER |
|---|
| fixed length control field |
04123nam a22004815i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20140310150242.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
130810s2013 gw | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9783642179075 |
|
978-3-642-17907-5 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
R-RZ |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
610 |
| Edition number |
23 |
| 264 #1 - |
|---|
| -- |
Berlin, Heidelberg : |
| -- |
Springer Berlin Heidelberg : |
| -- |
Imprint: Springer, |
| -- |
2013. |
| 912 ## - |
|---|
| -- |
ZDB-2-SBL |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Klebe, Gerhard. |
| Relator term |
editor. |
| 245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE |
|---|
| Title |
Drug Design |
| Medium |
[electronic resource] : |
| Remainder of title |
Methodology, Concepts, and Mode-of-Action / |
| Statement of responsibility, etc |
edited by Gerhard Klebe. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XV, 901 p. 496 illus., 333 illus. in color. eReference. |
| Other physical details |
online resource. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Part I Fundamentalsin Drug Research -- 1. Drug Research Yesterday, Today and Tomorrow -- 2. The Role of Serendipityin Drug Research -- 3. Classical Drug Research -- 4. Protein–Ligand Interactionsas the Basis for Drug Action -- 5. Optical Activity and Biological Effects -- Part II Discovery and Optimizationof Lead Compounds -- 6. Screeningfor Lead Structures -- 7. Screening Technologies for LeadDiscovery -- 8. Optimizationof Lead Structures -- 9. Designingprodrugs -- 10. Peptidomimetics -- Part III Experimental and Theoretical Methods -- 11. Combinatorics: Chemistry With Big Numbers -- 12. Gene Technology in drug research -- 13. Experimental Methods of Structure Determination -- 14. The Spatial Structure of Biomolecules -- 15. Molecular Modelling -- 16. Conformational Analysis -- Part IV Structure–Activity Relationships and Design Approaches -- 17.Pharmacophore Hypothesis and Molecular Comparisons -- 18. Quantitative Structure–ActivityRelationships -- 19. From in vitro to in vivo:Optimization of ADME-Tox Properties -- 20. ProteinModeling and Structure-BasedDrug Design -- 21. ACase Study: Structure-Based Inhibtor Design for tRNA-Guanine Transglycosylase -- Part V. Drugs and drug action: Successes of stucture-based design -- 22. Howdrugs act: Concepts for therapy -- 23. Inhibitors of hydrolases With an acyl-enzymeintermediate -- 24. Asparticprotease inhibitors -- 25. Inhibitorsof hydrolysing metalloenzymes -- 26. Inhibitorsof transferases -- 27. Inhibitors ofoxidoreductases -- 28. Agonists and antagonistsof nuclear receptors -- 29. Agonists and antagonists of membrane-bound -- 30. Ligands forchannels, pores and transporters -- 31. Ligands for surfacereceptors -- 32. Biologicals: Peptides, proteins, nucleotidesand macrolides as drugs. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
Unique work on structure-based drug design, covering multiple aspects of drug discovery and development. Fully colored, many images, computer animations of 3D structures (these only in electronic form). Makes the spatial aspects of interacting molecules clear to the reader, covers multiple applications and methods in drug design. Structures by mode of action, no therapeutic areas. Of high relevance for academia and industrial research. Focus on gene technology in drug design, omics-technologies computational methods experimental techniques of structure determination multiple examples on mode of action of current drugs, ADME-tox properties in drug development, QSAR methods, combinatorial chemistry, biologicals, ribosome, targeting protein-protein interfaces. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Medicine. |
|
|---|
| Topical term or geographic name as entry element |
Toxicology. |
|
|---|
| Topical term or geographic name as entry element |
Pharmaceutical technology. |
|
|---|
| Topical term or geographic name as entry element |
Biochemistry. |
|
|---|
| Topical term or geographic name as entry element |
Pharmacy. |
|
|---|
| Topical term or geographic name as entry element |
Biomedicine. |
|
|---|
| Topical term or geographic name as entry element |
Biomedicine general. |
|
|---|
| Topical term or geographic name as entry element |
Pharmacology/Toxicology. |
|
|---|
| Topical term or geographic name as entry element |
Pharmaceutical Sciences/Technology. |
|
|---|
| Topical term or geographic name as entry element |
Medicinal Chemistry. |
|
|---|
| Topical term or geographic name as entry element |
Pharmacy. |
|
|---|
| Topical term or geographic name as entry element |
Medicine/Public Health, general. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Display text |
Printed edition: |
| International Standard Book Number |
9783642179068 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-3-642-17907-5 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Item type |
E-Book |
